Omitting GnRH-antagonist Dose on the Day of Ovulation Trigger

Assiut University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Pituitary Downregulation

Treatments: Drug: Omit Citrotide 0.25 dose on the day of triggering of ovulation

Study type: Interventional

Funder types: Other

Identifiers

NCT03044756

Omit

Details and patient eligibility

About

Omitting the GnRH antagonist on the day of the trigger can be cost effective and more convenient to the women. We will study the impact of omitting the antagonist dose in a prospective randomized trial

Enrollment: 100 estimated patients

Sex: Female

Ages: 20 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All antagonist cycle ivf who agree to participate

Exclusion criteria

• expected poor responders.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups

-ve arm

Experimental group

Description:

The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)

Treatment:

Drug: Omit Citrotide 0.25 dose on the day of triggering of ovulation

+ve arm

No Intervention group

Description:

The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)